NASDAQ$GDRX
GoodRx Holdings Inc. · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
GoodRx reported results with revenue decreasing primarily due to a contract termination payment, partially offset by growth in prescription transactions revenue. They are working to rebuild momentum in the business with an eye toward compounding growth in 2024 and beyond.
GoodRx's third quarter 2023 results showed a revenue of $180.0 million, a decrease of 4% compared to the previous year. Adjusted Revenue increased by 1% to $190.0 million. The company reported a net loss of $38.5 million and an Adjusted EBITDA of $53.5 million.
- Revenue of $180.0 million; Adjusted Revenue of $190.0 million.
- Net loss of $38.5 million; Adjusted Net Income of $25.5 million.
- Adjusted EBITDA of $53.5 million.
- Exited the quarter with over 7 million consumers of prescription-related offerings.
Headline financials
Revenue & EPS history
GoodRx · Revenue · Quarterly
$180M
Revenue by segment
GoodRx · $175M total across 3 segments · Q3 2023
- Prescription Transactions$135M+3.2%77.6%
- Subscription$23.2M-12.5%13.3%
- Pharma Direct$15.9M-35.1%9.1%
Forward guidance
GoodRx is guiding to fourth quarter revenue and Adjusted Revenue in the range of $188 million to $194 million, representing 2%-5% year-over-year growth, and Adjusted EBITDA Margin in the mid-to-high twenty-percent range. They expect their 2024 Adjusted EBITDA Margin to meet or exceed 4Q23.
Tailwinds
- Fourth quarter revenue and Adjusted Revenue in the range of $188 million to $194 million, representing 2%-5% year-over-year growth
- Adjusted EBITDA Margin in the mid-to-high twenty-percent range
- The business is expected to grow next year at a roughly similar rate to the growth rate implied in the 4Q23 guide
- 2024 Adjusted EBITDA Margin is expected to meet or exceed 4Q23
- Balance sheet and liquidity position remained strong in the third quarter, while generating healthy cash flow from operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-5.3%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
37%
10 / 27 earnings
Positive
+29.1%
Q4 2023
Best reaction
-37.4%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +10.5% | +3.5% | |
| Q4 2025 | -19.5% | -15.5% | -20.8% | |
| Q3 2025 | +1.8% | -6.1% | -16.9% | |
| Q1 2025 | +11.9% | +13.5% | +7.7% | |
| Q4 2024 | +1.8% | -4.5% | -8.0% | |
| Q3 2024 | -20.0% | -23.1% | -19.6% | |
| Q2 2024 | -16.3% | -20.2% | -10.5% | |
| Q1 2024 | -13.3% | -12.6% | +12.4% | |
| Q4 2023 | +29.1% | +17.6% | +9.7% | |
| Q3 2023 | -12.4% | -8.8% | +9.1% | |
| Q2 2023 | -5.6% | -14.1% | -29.3% | |
| Q1 2023 | +7.0% | +10.9% | +17.5% | |
| Q4 2022 | +5.6% | +13.6% | +14.2% | |
| Q3 2022 | -21.5% | +10.4% | +0.8% | |
| Q2 2022 | +10.5% | +4.1% | -12.6% | |
| Q1 2022 | -37.4% | -30.1% | -43.5% | |
| Q4 2021 | -36.3% | -39.2% | -27.9% | |
| Q3 2021 | -5.7% | -5.1% | -5.4% | |
| Q2 2021 | +20.0% | +13.3% | +37.1% | |
| Q1 2021 | +5.1% | +2.4% | +24.8% | |
| Q4 2018 | -10.5% | -14.2% | -7.9% | |
| Q2 2020 | -3.9% | -7.8% | -1.2% | |
| Q4 2020 | -3.9% | -7.8% | -1.2% | |
| Q1 2020 | -7.3% | -29.1% | -16.5% | |
| Q3 2019 | -7.3% | -29.1% | -16.5% | |
| Q3 2020 | -7.3% | -29.1% | -16.5% | |
| Q4 2019 | -7.3% | -29.1% | -16.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro